Background: Clinical guidelines recommend that adults with hypertension self-monitor their blood pressure (BP).
S
elf-measured blood pressure (SMBP) monitoring refers to the measurement of BP by a patient at home or outside of a clinic setting. Clinical practice guidelines, including the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, recommend SMBP monitoring as an adjunct method in the management of hypertension (1) . The American Heart Association recommends SMBP measurements for evaluation of most patients with known or suspected hypertension to assess response to treatment and possibly improve adherence (2) . However, despite these recommendations, it is unclear whether SMBP monitoring confers benefit, and if so, for how long, and whether it needs to be combined with additional support (for example, education, counseling, telemedicine, or other measures) to facilitate BP measurement, transmission, interpretation, adherence to lifestyle measures and medication, or medication titration.
We conducted this systematic review to evaluate the effectiveness of SMBP monitoring at home with or without additional support in adults with hypertension. We examined the following comparisons: SMBP monitoring alone versus usual care, SMBP monitoring with additional support versus usual care, and SMBP monitoring with additional support versus SMBP monitoring with no additional support or with less intense additional support.
METHODS
This review is based on a comparative effectiveness review commissioned by the Agency for Healthcare Research and Quality (AHRQ) and published at www .effectivehealthcare.ahrq.gov (3) . It followed a standard AHRQ protocol and incorporated input from stakeholders, a technical expert panel, and peer review and public comments.
Data Sources and Search
We searched MEDLINE (inception to 8 February 2013 ) and the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (fourth quarter 2012) without language restriction (Appendix Table 1 , available at www.annals.org). Five reviewers independently screened abstracts using the computerized screening program abstrackr (Tufts Medical Center, Boston, Massachusetts) (4) after iteratively calibrating screening on an initial batch of 200 abstracts that were screened by all reviewers.
Study Selection
We included prospective comparative studies of SMBP monitoring with or without additional support versus usual care or versus SMBP monitoring with a different intervention and at least 8 weeks of follow-up. Selfmeasured BP had to be conducted in the patient's home, either by the patient or a companion. Patients had to be adults being managed for hypertension, whether treated or untreated, controlled or uncontrolled. We excluded studies in patients receiving dialysis or women with gestational hypertension, studies of SMBP monitoring as a component of disease management for heart failure or weight loss, and studies using only wrist monitors (because they are less reliable than upper arm monitors) (5) . We allowed studies that used wrist monitors as a default for patients with large arm circumference. All varieties of SMBP monitors (manual, semiautomated, or automated) were included. We categorized additional support post hoc as counseling, education, Web-based support, and miscellaneous support, according to the leading component (Appendix Table 2 , available at www.annals.org). Usual care included any protocol for clinic BP monitoring.
Clinical outcomes (including death and cardiovascular events), patient-reported outcomes (including patient satisfaction or quality of life), surrogate outcomes (including measures of left ventricular hypertrophy), intermediate outcomes (including BP; number, dose, or changes of antihypertensive medications; and adherence to antihypertensive medication), or health care utilization (including visits, calls, and e-mails) were of interest. For BP outcomes, we included systolic and diastolic BP or mean arterial pressure. These could be measured in the clinic by ambulatory BP or SMBP monitoring (if measured in both groups); BP could be reported as a continuous or categorical variable (for example, BP below a threshold).
Data Extraction, Quality Assessment, and Strength of Evidence
Each study was extracted by 1 of 5 reviewers with systematic review experience. Data on interventions, results, and quality grades were checked by another reviewer. The extracted data included study design, methods, participant characteristics, interventions (including SMBP device and protocol), additional support, comparators, and outcomes. We used a 3-category grading system (A, B, or C) to denote the methodological quality of each study for each outcome, in accordance with AHRQ's suggested methods for systematic reviews (6) .
Data Synthesis and Analysis
For continuous and binary clinic BP outcomes, we did random-effects model meta-analyses when similar data (including interventions and follow-up duration) were available from 3 or more randomized trials or comparisons. Comparisons of SMBP monitoring plus specific additional support (for example, an education program) versus the same support alone were analyzed as comparisons of SMBP monitoring alone versus usual care. We combined net differences for continuous outcomes (systolic and diastolic BP) and relative risk (RR) for the dichotomous outcome "adequate BP control." We allowed any definition or target of adequate control reported by a study. We assessed between-study heterogeneity with the Cochran Q test (significant when P Ͻ 0.10) and quantified its extent with the I 2 statistic (7). We summarized the strength of the evidence for an outcome category following the AHRQ methods guide as high, moderate, or low (6) . Ratings were assigned on the basis of our level of confidence that the evidence reflected the true effect for the comparisons of interest. Evidence was deemed insufficient if no studies existed or very few studies provided only sparse data.
Role of Funding Source
The work was funded by AHRQ. A technical expert panel and AHRQ helped to develop and refine the scope and assisted with review of draft reports. AHRQ granted copyright assertion before the manuscript could be submitted for publication, but the authors were solely responsible for the content and the decision to submit the manuscript for publication.
RESULTS

Study Characteristics
We identified 52 comparative studies (reported in 55 articles) (Appendix Figure, available Evidence for other outcomes is of low quality and inconsistent, but some studies found more medication changes and greater medication adherence with SMBP monitoring.
events, terminal illnesses, or advanced kidney disease). All but 2 studies were conducted in North America, Western Europe, or Australia (26, 46) . Minorities were underrepresented, although 4 studies focused on African American persons (8, 9, 14, 57) . In 33 studies, the device was specified to be an automated device.
BP Outcomes
SMBP Monitoring Alone Versus Usual Care
Of the 26 studies comparing SMBP monitoring alone versus usual care, 19 were included in meta-analyses for net changes in clinic systolic BP and diastolic BP (Figure 1) . Although there was no statistically significant difference in net change between SMBP monitoring and usual care at 2 months, SMBP monitoring was associated with statistically significant net changes in both systolic BP and diastolic BP at 6 months (weighted mean difference, Ϫ3.9 mm Hg and Ϫ2.4 mm Hg, respectively). These net changes were no longer statistically significant at 12-month follow-up (weighted mean difference, Ϫ1.5 mm Hg and Ϫ0.8 mm Hg, respectively). The summary estimates were essentially unchanged in sensitivity analyses that were restricted to quality A or B studies (data not shown). Meta-analyses showed a borderline statistically significant benefit of achieving a predefined BP target with SMBP monitoring versus usual care at 6 months, which lost significance at 12 months (Figure 1 in Supplement 1, available at www .annals.org). A sensitivity analysis that combined only the quality A and B studies showed a statistically significant result for adequate BP control at 6 months in favor of SMBP monitoring (data not shown). Eight studies that reported ambulatory BP outcomes were inconclusive.
Because of the consistency of findings in higherquality studies, statistically significant findings in metaanalyses at 6 months, and a nonstatistically significant finding at 12 months, the evidence for an improvement in BP using SMBP monitoring versus usual care is rated as moderate-strength and supports an improvement in BP with SMBP monitoring.
SMBP Monitoring Plus Additional Support Versus Usual Care
In the 25 studies that compared SMBP monitoring plus additional support versus usual care, additional support included educational materials, letters to patients and providers on treatment recommendations, Web resources, phone monitoring with electronic transmission of BP data, telecounseling, behavioral management, medication management with decision support, nurse or pharmacist visits, calendar pill packs, and adherence contracts (Appendix Table 2 ). Because of clinical heterogeneity, metaanalysis was not done. At 12 months, there was consistent benefit from the interventions compared with usual care, with 5 quality A studies reporting a mean net reduction in systolic BP (range, Ϫ2.1 to Ϫ8.3 mm Hg) or diastolic BP (range, 0.0 to Ϫ4.4 mm Hg) (9, 13, 29, 40, 52) (Figures  2 and 3) . The types of additional support in these 5 trials were telemonitoring and counseling on patient adherence to antihypertensive medications (9), Web-based pharmacist counseling (29) , telemonitoring with self-titration of antihypertensive medications (40) , telemonitoring with nurse videoconference (52) , and combined medicationbehavioral management (13) . Results were mixed at 18 months, with the single quality A trial finding no difference between groups. Two studies found statistically significant net reductions in systolic BP and diastolic BP at 24 to 60 months (13, 54) .
Twelve studies reported categorical BP outcomes, of which 5 reported that a statistically significantly higher proportion of patients achieved the BP target for SMBP monitoring plus additional support (Figure 1 in Supplement 1). Two trials provided ambulatory BP outcomes, both favoring SMBP monitoring with additional support (45, 48) .
On the basis of consistent findings in quality A trials, high-strength evidence supports a reduction in BP using SMBP monitoring with some form of additional support compared with usual care.
SMBP Plus Additional Support Versus SMBP Monitoring Alone or SMBP Monitoring Plus Less Intense Additional Support
Thirteen trials studied SMBP monitoring with additional support versus SMBP monitoring without additional support (or with less intensive additional support). Groups differed in additional support, such as behavioral interventions or disease management by a nurse or pharmacist, medication management, educational interventions, electronic transmission of BP measurements, Web sites or training for patient-provider communication, telemonitoring, BP recording cards, BP and medication tracking tool, hypertension information leaflets, or home visits.
Eleven studies (11-14, 17, 18, 20, 29, 32, 36, 39) showed mixed results for continuous clinic BP from the additional or more intensive support; only 1 showed statistically significant benefit for systolic and diastolic BP (29) (Figure 4) . Findings for categorical BP were similar ( Figure  2 in Supplement 1). One study evaluated 24-hour ambulatory BP (44) and found benefit from SMBP monitoring with telemonitoring for systolic BP but not for diastolic BP. Overall, the evidence is rated as low-strength and fails to support a difference between SMBP monitoring plus additional support versus SMBP monitoring with no additional support or with less intensive additional support in BP.
Other Outcomes for All Comparisons
Thirty-four studies provided data for other (non-BP) outcomes across all comparisons. Only 1 provided data on clinical outcomes (51) . The most commonly reported non-BP outcomes were related to medication use, quality of life, adherence, and health care encounters. These were generally not the primary study outcomes, and outcome definitions, methods for outcome assessment, and com- Net change of systolic (black circles) and diastolic (white circles) BP, with separate meta-analyses and P values and I 2 estimates, at different follow-ups. BP ϭ blood pressure; ND ϭ no data; NS ϭ not significant; SMBP ϭ self-measured blood pressure. * Study provided data at multiple time points.
pleteness of ascertainment varied. Therefore, strength of evidence for these surrogate outcomes was low. Findings were inconsistent, although a few studies showed more medication changes and better adherence with SMBP monitoring. For quality of life, no difference was found. For health care encounters, findings were inconsistent.
DISCUSSION
This review of 52 comparative studies on use of SMBP monitoring in adults with hypertension shows that for SMBP monitoring alone versus usual care, moderatestrength evidence supports a lower BP with SMBP monitoring at 6 months and possibly at 12 months. For SMBP monitoring plus additional support versus usual care, highstrength evidence supports a lower BP for up to 12 months. For SMBP monitoring plus additional support versus SMBP monitoring alone or with less intense additional support, low-strength evidence fails to support a difference for BP. The effect of SMBP monitoring on BP beyond 12 months and on clinical outcomes is uncertain. Evidence for other surrogate outcomes or health care encounters was low-strength and not conclusive. The findings of the review are applicable to adults with uncomplicated hypertension without recent acute illnesses who are willing and able to participate in SMBP monitoring at home.
Despite the ostensible similarity in research questions across studies, there was a large degree of variability in Net change of systolic (black circles) and diastolic (white circles) BP at different follow-ups. See Appendix Table 2 (available at www.annals.org) for full descriptions of letters in square brackets: C (counseling), E (education), W (Web-based), and M (miscellaneous). BP ϭ blood pressure; counsel ϭ counseling; mgt ϭ management; monitor ϭ monitoring; ND ϭ no data; Rx ϭ medication; SMBP ϭ self-measured blood pressure; tele ϭ telemedicine. * Study provided data at multiple time points.
Review
Self-Measured Blood Pressure Monitoring www.annals.orgSMBP monitoring protocols, transmission of and response to BP data, and types of additional support. Additional support varied in the primary intents, ancillary equipments, educational materials and encounters, qualification and effort of personnel, and algorithms for medication adjustments. Despite overlap, we categorized the additional support interventions as being based predominantly on education, counseling, Web support, or other support. However, no 2 studies used the same method of additional support, and even the studies that used SMBP monitoring without additional support varied in their methods. This makes it impossible to draw firm conclusions about the potential effects of specific methods or particular components of additional support or their interactions with SMBP monitoring. Nevertheless, with the caveat that evidence from indirect comparisons is inferior to that from Net change of systolic (black circles) and diastolic (white circles) BP at different follow-ups. See Appendix Table 2 (available at www.annals.org) for full descriptions of letters in square brackets: C (counseling), E (education), W (Web-based), and M (miscellaneous). BP ϭ blood pressure; counsel ϭ counseling; mgt ϭ management; monitor ϭ monitoring; Rx ϭ medication; SMBP ϭ self-measured blood pressure. * Study provided data at multiple time points. † References 52 and 54 are the same trial at different time points.
Review Self-Measured Blood Pressure Monitoring direct comparisons within trials, overall there is a suggestion that additional support is synergistic with SMBP monitoring to achieve BP control. The observed magnitude of BP reduction by SMBP monitoring with or without additional support would be clinically relevant on a population level if it was sustained over time. For example, a decrease of 2 or 5 mm Hg in systolic BP in the population has been estimated to result in mortality reductions of 6% or 14% due to stroke, 4% or 9% due to chronic heart disease, and 3% or 7% due to all causes (1, 63) . Beyond its effect on clinic BP, SMBP monitoring may be beneficial by allowing physicians to tailor treatment to a person's BP abnormality, thus avoiding overtreatment as well as undertreatment. Included studies recruited patients with controlled or uncontrolled hypertension but did not evaluate patients regarding their patterns of home and clinic BPs before inclusion. Further, studies differed in protocols for medication adjustment and Net change of systolic (black circles) and diastolic (white circles) BP. See Appendix Table 2 (available at www.annals.org) for full descriptions of letters in square brackets: C (counseling), E (education), W (Web-based), and M (miscellaneous). AS ϭ additional support; BP ϭ blood pressure; counsel ϭ counseling; mgt ϭ management; monitor ϭ monitoring; ND ϭ no data; Rx ϭ medication; SMBP ϭ self-measured blood pressure. * Study provided data at multiple time points. † Comparison is SMBP monitoring plus medication management vs. SMBP monitoring plus behavioral management. whether they were based on home or clinic BP levels and in the actual BP treatment target. Depending on the particular pattern between home and clinic BP in a given patient, the mix of patients in a study, and whether BP management was guided by home or clinic BP readings, SMBP monitoring may have resulted in opposing effects on medication management and clinic BP within and across studies. This is supported by the findings from Staessen and colleagues (64, 65) and Verberk and associates (60) , which compared adjustments in BP medication to achieve the same BP target for either home or clinic BP and found less intensive drug treatment but also less clinic BP control in the groups managed on the basis of home BP. Other possible benefits of SMBP monitoring are to engage patients and facilitate adherence to lifestyle modification. Estimates for cost-effectiveness of SMBP monitoring depend on the time horizon and assumptions for long-term benefit. In the short term, there may be greater resource utilization to respond to and treat BP, as well as costs for additional support (66, 67) . The evidence base has several limitations. Many studies were quality C and were likely underpowered, even for BP outcomes. Duration of follow-up in most instances was less than 12 months. Data on clinical outcomes were lacking. Given the clinical heterogeneity stemming from the variation in the populations, interventions, outcomes, and time points examined, often only 1 or 2 studies were available for specific comparisons.
To put our findings in the context of the current literature, we searched MEDLINE in February 2013 for reviews on this topic published since 2010. Three systematic reviews were published, each including between 14 and 37 trials (68 -70) . In contrast to our review, these other reviews did not require a minimum follow-up of 2 months, and 2 also included studies in patients receiving long-term hemodialysis. All reviews excluded nonrandomized studies, which we allowed. All found a statistically significant reduction in BP with SMBP monitoring, with net differences ranging from Ϫ2.5 to Ϫ3.8 mm Hg for systolic BP and Ϫ1.5 to Ϫ1.9 mm Hg for diastolic BP. Two additional reviews focused on the trials that used telemonitoring with SMBP monitoring and found that this led to a greater reduction in office BP (Ϫ4.71 mm Hg and Ϫ5.2 mm Hg for systolic BP; Ϫ2.45 and Ϫ2.1 mm Hg for diastolic BP) (67, 71) . One other review examined the effect of SMBP monitoring on medication adherence and found mixed results depending on the complexity of the additional support and the setting of primary care or hospital-based clinics (72) . To our knowledge, ours is the most comprehensive review to date. It involves the most studies, including a large, recently published trial (13) . It reviews BP effects over time, suggesting waning of the effect. Our comprehensive review of pertinent non-BP outcomes yielded only low-strength evidence. Our separation of comparisons into SMBP monitoring with or without additional support suggests that additional support and SMBP monitoring are synergistic.
In conclusion, SMBP monitoring lowers BP, but its sustainability and long-term clinical effectiveness remain uncertain. Future research is needed to determine the effect of SMBP monitoring on BP control beyond 12 months and long-term benefits of SMBP monitoring. Effects should be explored in persons stratified by patterns of home and clinic BPs and in subgroups (for example, older persons and those with cardiovascular and cerebrovascular disease, diabetes mellitus, and chronic kidney disease).
